...
首页> 外文期刊>Pharmacology: International Journal of Experimental and Clinical Pharmacology >Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors.
【24h】

Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors.

机译:激肽释放酶激肽系统在急性胰腺炎:潜在的B(2)-缓激肽拮抗剂和激肽释放酶抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

The development of selective antagonists for bradykinin B(2) receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the vascular symptoms, i.e. pancreatic oedema formation and its consequences, such as haemoconcentration, hypovolaemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B(2) antagonists must begin prior to the formation of pancreatic oedema in order to inhibit or attenuate the vascular effects. Visceral pain as a possible target symptom for treatment with B(2) antagonists at later time points is suggested by the B(2) receptor-mediated activation of nociceptive afferents. Copyright 2000 S. Karger AG, Basel.
机译:缓激肽B(2)受体选择性拮抗剂的开发已大大了解激肽释放酶激肽系统在急性胰腺炎中的作用。在炎症性损伤过程中释放的激肽是血管症状的主要原因,即胰腺水肿形成及其后果,例如血液浓缩,低血容量和低血压。激肽还参与胰腺组织中潜在细胞毒性因子的积累。但是,必须使用B(2)拮抗剂治疗才能形成胰腺水肿,才能抑制或减弱血管作用。 B(2)受体介导的伤害感受传入激活提示内脏疼痛是在以后的时间点用B(2)拮抗剂治疗的可能目标症状。版权所有2000 S. Karger AG,巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号